Intl. Biotechnology Trust PLC
22 May 2007
22 May 2007
C SHARE CONVERSION - ORDINARY SHARES LISTING DATE
Further to the announcement released on 17 May 2007, the Board of International
Biotechnology Trust plc (the 'Company') notifies a change in the timetable for
the expected listing of new Ordinary Shares once converted from C Shares.
In accordance with the Conversation Ratio already announced, the C Shares will
convert into Ordinary Shares immediately prior to the listing of the Ordinary
Shares on the London Stock Exchange. The new Ordinary Shares are now expected
to list on the London Stock Exchange at 8.00 am on 24 May. An application will
be made to cancel the listing of the C Shares with effect from 24 May 2007.
Enquiries:
Cenkos Securities Will Rogers
020 7397 8900
SV Life Sciences Managers Andy Smith/Kate Bingham
020 7421 7070
Lansons Communications Henrietta Guthrie/Amy Fisher/Charlotte Edgar
020 7490 8828
International Biotechnology Trust plc Andrew Barker, Chairman
020 7658 6501
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.